Acquisitions, Investments, and Licenses - Textual (Details)	3 Months Ended		9 Months Ended			1 Months Ended		1 Months Ended	0 Months Ended				1 Months Ended	12 Months Ended		1 Months Ended			9 Months Ended	1 Months Ended			1 Months Ended	0 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Dec. 31, 2013 USD ($)	Jun. 30, 2012 SciVac Variable Interest Entity, Primary Beneficiary USD ($) member	Sep. 30, 2014 SciVac Variable Interest Entity, Primary Beneficiary USD ($)	Oct. 31, 2013 Equity Method Investee USD ($)	Jan. 16, 2014 Biozone Equity Method Investee USD ($)	Jan. 16, 2014 Biozone Equity Method Investee	Jan. 02, 2014 Biozone Equity Method Investee	Jan. 02, 2014 Biozone Equity Method Investee Series B Convertible Preferred Stock	Oct. 31, 2013 ARNO Equity Method Investee USD ($)	Dec. 31, 2013 Neovasc USD ($)	Dec. 31, 2011 Neovasc USD ($)	Jan. 31, 2014 Pharmsynthez	Apr. 30, 2013 Pharmsynthez USD ($)	Apr. 30, 2013 Pharmsynthez RUB	Sep. 30, 2014 Pharmsynthez USD ($)	Mar. 31, 2013 RXi Pharmaceuticals Corporation USD ($)	Oct. 31, 2013 Zebra USD ($)	Oct. 31, 2013 Zebra Series A Preferred Stock	Oct. 31, 2013 Zebra Restricted Stock	May 16, 2014 Senesco Common stock investments, available for sale	May 16, 2014 Senesco Common stock investments, available for sale	May 16, 2014 Fabrus Common stock investments, available for sale	Oct. 31, 2013 One Year Warrants ARNO Equity Method Investee	Oct. 31, 2013 Five Year Warrants ARNO Equity Method Investee	Apr. 17, 2014 Inspiro USD ($)	Apr. 17, 2014 Inspiro USD ($)	Aug. 31, 2013 OPKO Biologics USD ($)	Aug. 08, 2014 OPKO Renal	Mar. 31, 2013 OPKO Renal USD ($)	Aug. 08, 2014 OPKO Renal USD ($)
Business Acquisition [Line Items]
Inspiro stock purchase agreement																														100.00%
Cash paid at closing date						$ 700,000																							$ 1,500,000
Common stock value																														8,600,000	540,600,000		146,900,000	21,200,000
Number of trading days																													10 days				10 days
Stock price	$ 0.36		$ 0.36																											$ 8.57	$ 8.49		$ 7.16	$ 9.46
In process research and development	0	0	10,055,000	0																									10,100,000
Shares conversion ratio																															0.9951
Delivery of common stock																													999,556		63,670,805	2,236,210	20,517,030
Options and warrants outstanding (shares)																															7,889,265
Fair value of warrants outstanding																															46,100,000
Percentage of ownership held by chairman																															5.00%
Percentage of ownership held by directors																															5.00%
Business acquisition share price on shares issue																													$ 9.00				$ 4.87
Amount payable in cash or shares on achieving milestones for acquiring a product in development																																	190,000,000
Contingent consideration	71,200,000		71,200,000		71,600,000																												47,700,000
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued												1,000,000
Stock Conversion, Common Shares Issued upon Conversion											205.08
Class of Warrant or Right, Expiration Period										10 years
Invested in common shares									500,000				2,000,000	1,200,000	2,000,000					2,500,000	2,000,000
Private Placement Financing								30,000,000	2,750,000
Warrants to purchase common shares										1,000,000					1,000,000												833,333	833,333
Class of Warrant or Right, Exercise Price of Warrants or Rights										0.50																	2.40	4.00
Warrants expiration period															2 years												1 year	5 years
Number of shares purchased															2,000,000		13,600,000	13,600,000		17,241,380
Investment Warrants, Exercise Price															$ 1.25
Asset Purchase Agreement																	9,600,000
Number of share options received in purchase agreement																	12,000,000	12,000,000
Proceeds to be received from sale of proprietary technology																	8,100,000	265,000,000
Shares Received In Satisfaction of Notes Receivable																12,000,000
Deferred revenue	7,700,000		7,700,000		8,300,000												9,500,000
Period for development of technology																	3 years	3 years
Deferred revenue received from collaboration agreement																			1,700,000
Revenue related to our license agreements																			500,000
Revenue collaboration agreement, offset to research and development																			1,200,000
Issue of common stock shares																				50,000,000
Milestone payments																				50,000,000
Asset purchase agreement financing for Rxi																				16,400,000
Conversion of Stock, Shares Converted																								80,000
Shares, Outstanding																										1,159,380
Equity Method Investment, Third Party Purchase of Investment, Conversion of Shares, Shares Issued in New Entity																								437,016
Investment Owned, Balance, Shares										1,000,000			833,333									840,000			517,016
Number of Shares Warrants Acquired in Equity Method Investment																								267,927
Cocrystal on a fully diluted basis						50.00%
Additional working capital							4,400,000
Number of members of board of directors						5
Number of members of board of directors appointed by reporting entity						3
Percent of board of directors appointed by reporting entity						60.00%
Shares Received As Gift																							900,000
Equity Method Investment, Ownership Percentage																						23.50%
Total assets of equity method investees	127,800,000		127,800,000
Total liabilities of equity method investees	(18,800,000)		(18,800,000)
Net losses of equity method investees			$ 31,300,000